|
Upcoming HOTopics Webinar:
February 2, at 1 pm CST
Space is limited to 100 registrations
New Cytotoxic Chemotherapy Agents Approved For Metastatic Breast Cancer And Hormone Refractory Prostate Cancer
Topic One: Eribulin Improves Overall Survival as a Third Line Agent in Metastatic Breast Cancer
Speaker: Michael J. Berger, PharmD
Specialty Practice Pharmacist
The Arthur G. James Cancer Hospital
Objectives:
- Describe the role of eribulin in the treatment of metastatic breast cancer.
- Discuss the need for dosage adjustment for hepatic and renal impairment.
- Illustrate the appropriate management of the dose limiting toxicities identified for eribulin.
Topic Two: Cabazitaxel as a Second Line Agent for Hormone Refractory Prostate Cancer
Speaker: Sherry L. Mori Vogt, PharmD
Specialty Practice Pharmacist
The Arthur G. James Cancer Hospital
Objectives:
- Describe the role of cabazitaxel in the treatment of hormone refractory prostate cancer.
- Discuss the appropriate dosage for cabazitaxel in combination with prednisone.
- Illustrate the appropriate management of the serious adverse events associated with cabazitaxel.
Moderator: Brandy Marie Strickland, PharmD BCOP
Hematology Oncology Pediatric Clinical Coordinator
Wake Forest University Baptist Medical Center
Reserve your Webinar seat now at:
https://www3.gotomeeting.com/register/134217470
After registering you will receive a confirmation email containing information about joining the Webinar.
|
